Tonix Pharmaceuticals Holding Investor Presentation — January 2021 - Tonix Pharmaceuticals Holding Corp.

Document content

Version P0267 1-5 -2021 (Doc 0756)Investor Presentation

Certain statements inthispresentation regarding strategic plans, expectations andobjectives forfuture

operations orresults are“forward -looking statements” asdefined bythePrivate Securities Litigation Reform

Actof1995.These statements may beidentified bytheuseofforward -looking words such as“anticipate,”

“believe,” “forecast,” “estimate” and“intend,” among others .These forward -looking statements arebased on

Tonix’s current expectations andactual results could differ materially .There areanumber offactors that

could cause actual events todiffer materially from those indicated bysuch forward -looking statements. These

factors include, butarenotlimited to,risks related tofailure toobtain U.S.Food andDrug Administration

clearances orapprovals andnoncompliance withitsregulations ;ourneed foradditional financing ;delays and

uncertainties caused bytheglobal COVID -19pandemic; substantial competition ;uncertainties ofpatent

protection andlitigation ;uncertainties ofgovernment orthird party payor reimbursement ;limited research

anddevelopment efforts anddependence upon third parties .Aswithanypharmaceutical under development,

there aresignificant risks inthedevelopment, regulatory approval andcommercialization ofnewproducts .

Theforward -looking statements inthispresentation aremade asofthedate ofthispresentation, even if

subsequently made available byTonix onitswebsite orotherwise .Tonix does notundertake anobligation to

update orrevise anyforward -looking statement, except asrequired bylaw.Investors should read therisk

factors setforth intheAnnual Report onForm 10-Kfortheyearended December 31,2019,asfiledwiththe

Securities andExchange Commission (the“SEC”) onMarch 24,2020, andperiodic reports andcurrent reports

filed with theSEConorafter thedate thereof .AllofTonix's forward -looking statements areexpressly

Clinical -stage biopharmaceutical company

•Committed to discovering and developing innovative and proprietary new

Focus on developing biologics and small molecules

•Central Nervous System (CNS)

•Lead: fibromyalgia program in mid- Phase 3

•Pipeline: Pain, neurology, psychiatry, addiction

•Lead: COVID -19 vaccine in non -human primate testing